Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918461 | 0.72 | CYP2C19 (0.40) | KMT2AL3MBTL1GAAMGAMSI | |
| SCHEMBL10502950 | 0.70 | KMT2A (0.38) | KMT2AL3MBTL1TSHRPOLBALDH1A1 | |
| SCHEMBL10505164 | 0.70 | KMT2A (0.38) | KMT2AL3MBTL1TSHRPOLBALDH1A1 | |
| Hydrochloric Acid SCHEMBL1141217 | 0.68 | POLB (0.41) | KMT2AALOX15POLBALDH1A1ATM | |
| SCHEMBL10469549 | 0.68 | POLB (0.45) | KMT2AL3MBTL1GAAMGAMSI | |
| SCHEMBL16753659 | 0.67 | GAA (0.48) | KMT2AL3MBTL1GAAMGAMSI | |
| SCHEMBL15776045 | 0.66 | KMT2A (0.42) | KMT2AL3MBTL1GAAMGAMSI | |
| SCHEMBL19016865 | 0.66 | GAA (0.46) | KMT2AL3MBTL1GAAMGAMSI | |
| Malonic Acid Diethyl Ester SCHEMBL8417856 | 0.65 | GAA (0.94) | KMT2AL3MBTL1GAAMGAMSI | |
| SCHEMBL6821512 | 0.64 | KMT2A (0.45) | KMT2AL3MBTL1GAAMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SUZHOU ZELGEN BIOPHARMACEUTICALS CO., LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4497751-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Suzhou Zelgen Biopharmaceuticals Co., Ltd. (CN) | 2025-01-29 | — | — | EP | disclosed |
| CN-119317628-A | Substituted bridged ring inhibitors and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024149389-A1 | SUBSTITUTED BRIDGE RING INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 苏州泽璟生物制药股份有限公司 | 2024-07-18 | — | — | WO | disclosed |
| CN-118344386-A | Substituted bridged ring inhibitors and preparation method and application thereof | 苏州泽璟生物制药股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206758-A1 | SUBSTITUTED BRIDGED RING INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | KRAS, WEE1, NRAS | KMT2A 1782/4885L3MBTL1 3154/4885GAA 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.